X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Study Links Early Infections to Celiac Risk

Yuvraj_pawp by Yuvraj_pawp
5th October 2015
in Americas, News

Children who have a lot of infections in the first 18 months of life may have an increased risk for celiac disease, a new study from Norway suggests.

The study found that children with 10 or more respiratory and gastrointestinal infections during the first 18 months of life were 30 percent more likely to develop celiac disease than kids who had fewer than five infections. The researchers also found that youngsters with repeated respiratory infections were at greater risk than those with repeated gastrointestinal infections.

“We think there are many pieces to the puzzle that must fit together for someone to develop celiac disease, where heredity, gluten intake and possibly many other environmental factors are important,” study first author Dr. Karl Marild, from the Norwegian Institute of Public Health in Oslo, said in an institute news release.

“Perhaps having frequent infections in early life influences the immune system so that it is subsequently more likely to react to gluten,” Marild said.

The study’s findings were published recently in The American Journal of Gastroenterology.

However, while the study linked a greater number of infections with an increased risk of celiac disease, it did not prove a cause-and-effect relationship. It’s possible that children who had more infections were more likely to be diagnosed with celiac simply because they spent much more time in the health care system, the researchers said.

“We cannot rule out that the association found may somewhat have been influenced by increased health care surveillance, including diagnostic workup for celiac disease, among the children with high infection frequency,” Marild said.

People with celiac disease can’t eat gluten, a protein found in wheat, rye and barley. If someone with celiac eats gluten, it triggers a damaging immune-system response in their bodies, the researchers explained.

For the study, the researchers analyzed information from nearly 73,000 children born in Norway. The children were born between 2000 and 2009, and the average follow-up time was 8.5 years. Just under 1 percent of the children eventually developed celiac disease, the study found.

Tags: America
Previous Post

Higher-Volume Rehab Centers Better for Hip Fracture Recovery: Study

Next Post

The 9th Asian & Oceanic epilepsy Congress

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Next Post

The 9th Asian & Oceanic epilepsy Congress

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In